Related references
Note: Only part of the references are listed.Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer
Deli Hong et al.
CANCER RESEARCH (2022)
Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium
Jasmine Chen et al.
ONCOGENE (2022)
Antibody ? drug conjugates for lung cancer in the era of personalized oncology
Biagio Ricciuti et al.
SEMINARS IN CANCER BIOLOGY (2021)
Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
Xiaoting Ma et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling
Meng Zheng et al.
Aging-US (2021)
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
Daniel J. Lindner et al.
BRITISH JOURNAL OF CANCER (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Mingrui Zhu et al.
CANCER RESEARCH (2021)
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Joseph M. Chan et al.
CANCER CELL (2021)
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang et al.
NATURE COMMUNICATIONS (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
D. R. Spigel et al.
ANNALS OF ONCOLOGY (2021)
Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer
Yang Zheng et al.
CANCER LETTERS (2021)
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution
Lei Zhao et al.
ONCOGENE (2021)
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Navin R. Mahadevan et al.
CANCER DISCOVERY (2021)
Trilaciclib: First Approval
Sohita Dhillon
DRUGS (2021)
Aberrant methylation modifications reflect specific drug responses in small cell lung cancer
Peixin Chen et al.
GENOMICS (2021)
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC
L. Portia Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cancer/testis antigens: from serology to mRNA cancer vaccine
Chunmei Fan et al.
SEMINARS IN CANCER BIOLOGY (2021)
PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer
Zibo Zhao et al.
CANCER RESEARCH (2021)
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
Manuel Domine Gomez et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells
Haeryung Cho et al.
MOLECULES (2021)
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Luke Maggs et al.
TRENDS IN CANCER (2021)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
Xi Chen et al.
ACTA PHARMACEUTICA SINICA B (2020)
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Hua Zhang et al.
CANCER CELL (2020)
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Kelly Olino et al.
SEMINARS IN CANCER BIOLOGY (2020)
Combining epigenetic and immune therapy to overcome cancer resistance
Stephanie Gomez et al.
SEMINARS IN CANCER BIOLOGY (2020)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
Julia Krushkal et al.
CLINICAL EPIGENETICS (2020)
hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance (Publication with Expression of Concern. See vol. 62, pg. 556, 2021)
Guangsheng Zhai et al.
JOURNAL OF RADIATION RESEARCH (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich et al.
CANCER RESEARCH (2020)
Targeting the epigenetic regulation of antitumour immunity
Simon J. Hogg et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
Camille Tlemsani et al.
CELL REPORTS (2020)
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Jian Cao et al.
TRENDS IN CANCER (2020)
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Arnaud Augert et al.
SCIENCE SIGNALING (2019)
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
Todd M. Bauer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L. Burr et al.
CANCER CELL (2019)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis
Matthew G. Oser et al.
GENES & DEVELOPMENT (2019)
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Hyunchul Jung et al.
NATURE COMMUNICATIONS (2019)
Epigenetic therapy in immune-oncology
Peter A. Jones et al.
NATURE REVIEWS CANCER (2019)
CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter
Zhengang Qiu et al.
THERANOSTICS (2019)
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells
Sarmishtha De et al.
CANCER RESEARCH (2018)
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model
Yan Liu et al.
CANCER RESEARCH (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Na Luo et al.
NATURE COMMUNICATIONS (2018)
Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
Deshui Jia et al.
CANCER DISCOVERY (2018)
H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR
Shun Fang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Mary Philip et al.
NATURE (2017)
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
David Brocks et al.
NATURE GENETICS (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome
Paul Maddison et al.
NEUROLOGY (2017)
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Loredana Cifaldi et al.
TRENDS IN MOLECULAR MEDICINE (2017)
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition
Teresa Ezponda et al.
CELL REPORTS (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Epigenetic modification of nucleic acids: from basic studies to medical applications
Yuqi Chen et al.
CHEMICAL SOCIETY REVIEWS (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells
Shun Fang et al.
LABORATORY INVESTIGATION (2016)
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Nita Ahuja et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Chun-Hao Pan et al.
BMC CANCER (2016)
Design and synthesis of selective, small molecule inhibitors of coactivator-associated arginine methyltransferase 1 (CARM1)
H. U. Kaniskan et al.
MEDCHEMCOMM (2016)
Histone Modifications and Cancer
James E. Audia et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells
Fei Yan et al.
PLOS ONE (2016)
Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition
C. Allison Stewart et al.
CANCER CELL (2015)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave et al.
NATURE MEDICINE (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
J. T. Poirier et al.
ONCOGENE (2015)
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells
Xue Zhang et al.
EPIGENETICS & CHROMATIN (2014)
Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells
Dong Yeok Shin et al.
BIOMEDICINE & PHARMACOTHERAPY (2013)
DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer
Jianzhong Cao et al.
CANCER RESEARCH (2013)
An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
Alison C. West et al.
CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
Filippo de Marinis et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells
S. Kalari et al.
ONCOGENE (2013)
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine- DNA Methyltransferase as a Potential Biomarker
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2012)
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
Kwang Hwa Jung et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1
Y. Liu et al.
ONCOGENE (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
A Genetic Snapshot of Small Cell Lung Cancer
Rafael Rosell et al.
CANCER DISCOVERY (2012)
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
Vitaliy O. Kaminskyy et al.
CARCINOGENESIS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The Histone Chaperone FACT: Structural Insights and Mechanisms for Nucleosome Reorganization
Duane D. Winkler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Loss of Glucocorticoid Receptor Expression by DNA Methylation Prevents Glucocorticoid Induced Apoptosis in Human Small Cell Lung Cancer Cells
Paul Kay et al.
PLOS ONE (2011)
Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression
Wioleta Luszczek et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model
V. El-Khoury et al.
BRITISH JOURNAL OF CANCER (2007)
Share Paper
